PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Go back to PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
(NASDAQ: SPTX) Delayed: 20.01 +0.41 (2.09%)
Previous Close $19.60    52 Week High $ 
Open $19.68    52 Week Low $ 
Day High $21.07    P/E N/A 
Day Low $19.13    EPS $ 
Volume 527,903